Positive phase 1 data from mrna-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer presented at asco

Mainz, germany and chicago, june 5, 2022 (globe newswire) – biontech se (nasdaq: bntx, “biontech”) today announced initial data from an ongoing investigator-initiated first-in-human phase 1 study evaluating the safety and tolerability of the mrna-based individualized neoantigen specific immunotherapy (inest) autogene cevumeran (also known as bnt122, ro7198457) in combination with anti-pd-l1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (pdac). feasibility of the process of profiling each patient's tumor to inform individualized vaccine design and on-demand manufacturing of inest in a clinically relevant timeframe was confirmed. the preliminary results showed a favorable safety profile as well as encouraging signs of clinical activity. the data have been presented at the american society of clinical oncology (“asco”) annual meeting 2022 by vinod balachandran, m.d., at memorial sloan kettering cancer center. autogene cevumeran is the lead candidate from biontech's inest platform, which is jointly developed together with genentech, a member of the roche group, in multiple solid tumor indications.
BNTX Ratings Summary
BNTX Quant Ranking